ECSP099639A - Compuestos amino-5-[-4-(difluorometoxi)fenil sustituido]-5-fenilimidazolona como inhibidores de ?-secretasa - Google Patents
Compuestos amino-5-[-4-(difluorometoxi)fenil sustituido]-5-fenilimidazolona como inhibidores de ?-secretasaInfo
- Publication number
- ECSP099639A ECSP099639A EC2009009639A ECSP099639A ECSP099639A EC SP099639 A ECSP099639 A EC SP099639A EC 2009009639 A EC2009009639 A EC 2009009639A EC SP099639 A ECSP099639 A EC SP099639A EC SP099639 A ECSP099639 A EC SP099639A
- Authority
- EC
- Ecuador
- Prior art keywords
- optionally substituted
- alkyl
- group
- independently
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- -1 cycloheteroalkyl Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 abstract 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000006999 cognitive decline Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 abstract 1
- 125000000262 haloalkenyl group Chemical group 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto de la Fórmula I. en donde R1 y R2 son cada uno independientemente H o un grupo alquilo, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo cada uno se sustituye opcionalmente o R1 y R2 se pueden tomar junto con el átomo al cual ellos se adhieren para formar un anillo de 5 a 7 miembros opcionalmente sustituido que se interrumpe opcionalmente por un heteroátomo adicional seleccionado de O, N o S; R3 es H o un grupo alquilo, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo cada uno se sustituye opcionalmente;R4, R5 y R6 son cada uno independientemente H, halógeno, NO2, CN, COR9, NR10CO2R11, NR12R13, OR14, NR15COR16, SOnR17 o un grupo alquilo, haloalquilo, alquenilo, haloalquenilo, alquinilo, cicloalquilo, alcoxi, alqueniloxi, alquiniloxi o cicloheteroalquilo cada uno se sustituye opcionalmente o cuando se adhieren a los átomos de carbono adyacentes R4 y R5 se pueden tomar junto con los átomos a los cuales ellos se adhieren para formar un anillo de 5 a 7 miembros opcionalmente sustituido que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N o S;n es 0, 1 o 2;R7 y R8 son cada uno independientemente H, halógeno, NR20R21 o un grupo alquilo, cicloalquilo o alcoxi cada grupo se sustituye opcionalmente con la condición que uno de R7 o R8 puede ser diferente a H;R9 y R17 son cada uno independientemente H, NR18R19 o un grupo alquilo, haloalquilo, alcoxialquilo, alquenilo, alquinilo, cicloalquilo o arilo cada uno se sustituye opcionalmente;R10 y R15 son cada uno independientemente H o un grupo alquilo opcionalmente sustituido; R11, R14 y R16 son cada uno independientemente H o un grupo alquilo, haloalquilo, alcoxialquilo, alquenilo, alquinilo, cicloalquilo o arilo cada uno se sustituye opcionalmente;R12 y R13 son cada uno independientemente H o un grupo alquilo o cicloalquilo cada uno se sustituye opcionalmente o R12 y R13 se pueden tomar junto con el átomo al cual ellos se adhieren para formar un anillo de 5 a 7 miembros opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional seleccionado de O, N o S; R18 y R19 son cada uno independientemente H o un grupo alquilo, alquenilo, alquinilo o cicloalquilo cada uno se sustituye opcionalmente o R18 y R19 se pueden tomar junto con el átomo al cual ellos se adhieren para formar un anillo de 5 a 7 miembros opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional seleccionado de O, N o S; R20 y R21 son cada uno independientemente H, COR22 o un grupo alquilo opcionalmente sustituido; yR22 es un grupo alquilo opcionalmente sustituido; oun tautómero de estos, un estereoisómero de estos o una sal farmacéuticamente aceptable de estos.La presente invención también se relaciona con el uso de tales compuestos para el tratamiento de los depósitos -amiloides y ovillos neurofibrilares. Los compuestos de la Fórmula I son particularmente útiles en el tratamiento de la Enfermedad de Alzheimer, deterioro cognitivo, Síndrome de Down, HCHWA-D, disminución cognitiva, demencia senil, angiopatía amiloide cerebral, demencia degenerativa, o otros trastornos neurodegenerativos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91908707P | 2007-03-20 | 2007-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099639A true ECSP099639A (es) | 2009-10-30 |
Family
ID=39564223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009639A ECSP099639A (es) | 2007-03-20 | 2009-09-18 | Compuestos amino-5-[-4-(difluorometoxi)fenil sustituido]-5-fenilimidazolona como inhibidores de ?-secretasa |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20090042964A1 (es) |
| EP (1) | EP2137161A1 (es) |
| JP (1) | JP2010522235A (es) |
| KR (1) | KR20100015376A (es) |
| CN (1) | CN101641335A (es) |
| AR (1) | AR065811A1 (es) |
| AU (1) | AU2008229327A1 (es) |
| BR (1) | BRPI0808944A2 (es) |
| CA (1) | CA2681243A1 (es) |
| CL (1) | CL2008000784A1 (es) |
| CO (1) | CO6140056A2 (es) |
| CR (1) | CR11020A (es) |
| EC (1) | ECSP099639A (es) |
| GT (1) | GT200900241A (es) |
| IL (1) | IL200961A0 (es) |
| MX (1) | MX2009009699A (es) |
| NI (1) | NI200900164A (es) |
| PA (1) | PA8772701A1 (es) |
| PE (1) | PE20090160A1 (es) |
| RU (1) | RU2009133807A (es) |
| SV (1) | SV2009003373A (es) |
| TW (1) | TW200845965A (es) |
| WO (1) | WO2008115552A1 (es) |
| ZA (1) | ZA200906542B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| SG162790A1 (en) | 2005-06-14 | 2010-07-29 | Schering Corp | Aspartyl protease inhibitors |
| EP2324032B1 (en) | 2008-08-19 | 2014-10-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| EP2184276A1 (en) * | 2008-11-07 | 2010-05-12 | Universite Paul Cezanne Aix-Marseille Iii | Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors |
| EA020875B1 (ru) | 2009-03-13 | 2015-02-27 | Вайтаи Фармасьютиклз, Инк. | Ингибиторы бета-секретазы |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US8889703B2 (en) | 2010-02-24 | 2014-11-18 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US9181236B2 (en) | 2011-08-22 | 2015-11-10 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
| TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β－分泌酶抑制劑 |
| TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β－分泌酶抑制劑 |
| EP2900650A1 (en) | 2012-09-28 | 2015-08-05 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| CA2899938C (en) | 2013-02-12 | 2021-10-19 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| US20160298151A1 (en) | 2015-04-09 | 2016-10-13 | Sher Ali Butt | Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products |
| CA3096505A1 (en) * | 2018-04-23 | 2019-10-31 | Merck Sharp & Dohme Corp. | Novel process for synthesis of a phenoxy diaminopyrimidine compound |
| CN109289696B (zh) * | 2018-10-29 | 2022-03-22 | 天津先光化工有限公司 | 一种咪唑啉两性表面活性剂的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE45198B1 (en) * | 1976-06-05 | 1982-07-14 | Wyeth John & Brother Ltd | Guanidine derivatives |
| GB1588096A (en) * | 1978-05-20 | 1981-04-15 | Wyeth & Bros Ltd John | Pyrrole derivatives |
| GB9511694D0 (en) * | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6492408B1 (en) * | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| DE10046993A1 (de) * | 2000-09-22 | 2002-04-11 | Aventis Pharma Gmbh | Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament |
| WO2003094854A2 (en) * | 2002-05-07 | 2003-11-20 | Elan Pharmaceuticals, Inc. | Succinoyl aminopyrazoles and related compounds |
| US7700603B2 (en) * | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| ATE444962T1 (de) * | 2004-06-16 | 2009-10-15 | Wyeth Corp | Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung |
| JP2008503460A (ja) * | 2004-06-16 | 2008-02-07 | ワイス | β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン |
| EP2264036A1 (en) * | 2005-01-14 | 2010-12-22 | Wyeth LLC (Formerly Known As Wyeth) | Amino-imidazolones for the inhibition of beta-secretase |
| BRPI0607094A2 (pt) * | 2005-02-01 | 2009-08-04 | Wyeth Corp | composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica |
| CN101146769A (zh) * | 2005-02-14 | 2008-03-19 | 惠氏公司 | 作为β-分泌酶抑制剂的唑基酰基胍 |
| WO2006088705A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Terphenyl guanidines as [beta symbol] -secretase inhibitors |
| WO2006088694A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS |
| TW200738683A (en) * | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| JP2009500329A (ja) * | 2005-06-30 | 2009-01-08 | ワイス | アミノ−５−（６員）ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用 |
| TW200730523A (en) * | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| AU2006294620A1 (en) * | 2005-09-26 | 2007-04-05 | Wyeth | Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace) |
| JP2009520027A (ja) * | 2005-12-19 | 2009-05-21 | ワイス | ２−アミノ−５−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用 |
| WO2007100536A1 (en) * | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| US7700606B2 (en) * | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
| MX2009003102A (es) * | 2006-09-21 | 2009-04-01 | Wyeth Corp | INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA. |
-
2008
- 2008-03-18 CL CL200800784A patent/CL2008000784A1/es unknown
- 2008-03-18 PE PE2008000494A patent/PE20090160A1/es not_active Application Discontinuation
- 2008-03-19 PA PA20088772701A patent/PA8772701A1/es unknown
- 2008-03-19 AR ARP080101180A patent/AR065811A1/es unknown
- 2008-03-20 WO PCT/US2008/003681 patent/WO2008115552A1/en not_active Ceased
- 2008-03-20 EP EP08727031A patent/EP2137161A1/en not_active Withdrawn
- 2008-03-20 US US12/052,098 patent/US20090042964A1/en not_active Abandoned
- 2008-03-20 BR BRPI0808944-2A patent/BRPI0808944A2/pt not_active Application Discontinuation
- 2008-03-20 CN CN200880008871A patent/CN101641335A/zh active Pending
- 2008-03-20 TW TW097109933A patent/TW200845965A/zh unknown
- 2008-03-20 RU RU2009133807/04A patent/RU2009133807A/ru not_active Application Discontinuation
- 2008-03-20 JP JP2010500934A patent/JP2010522235A/ja not_active Withdrawn
- 2008-03-20 MX MX2009009699A patent/MX2009009699A/es not_active Application Discontinuation
- 2008-03-20 KR KR1020097020772A patent/KR20100015376A/ko not_active Withdrawn
- 2008-03-20 CA CA002681243A patent/CA2681243A1/en not_active Abandoned
- 2008-03-20 AU AU2008229327A patent/AU2008229327A1/en not_active Abandoned
-
2009
- 2009-09-04 NI NI200900164A patent/NI200900164A/es unknown
- 2009-09-09 CR CR11020A patent/CR11020A/es unknown
- 2009-09-10 GT GT200900241A patent/GT200900241A/es unknown
- 2009-09-15 IL IL200961A patent/IL200961A0/en unknown
- 2009-09-16 CO CO09100417A patent/CO6140056A2/es unknown
- 2009-09-18 ZA ZA200906542A patent/ZA200906542B/xx unknown
- 2009-09-18 SV SV2009003373A patent/SV2009003373A/es not_active Application Discontinuation
- 2009-09-18 EC EC2009009639A patent/ECSP099639A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8772701A1 (es) | 2008-11-19 |
| AU2008229327A1 (en) | 2008-09-25 |
| GT200900241A (es) | 2010-05-07 |
| PE20090160A1 (es) | 2009-02-11 |
| TW200845965A (en) | 2008-12-01 |
| AR065811A1 (es) | 2009-07-01 |
| CN101641335A (zh) | 2010-02-03 |
| SV2009003373A (es) | 2010-08-10 |
| NI200900164A (es) | 2010-07-29 |
| EP2137161A1 (en) | 2009-12-30 |
| ZA200906542B (en) | 2010-06-30 |
| US20090042964A1 (en) | 2009-02-12 |
| CA2681243A1 (en) | 2008-09-25 |
| IL200961A0 (en) | 2010-05-17 |
| JP2010522235A (ja) | 2010-07-01 |
| RU2009133807A (ru) | 2011-04-27 |
| AU2008229327A8 (en) | 2009-10-15 |
| WO2008115552A1 (en) | 2008-09-25 |
| CO6140056A2 (es) | 2010-03-19 |
| BRPI0808944A2 (pt) | 2014-09-02 |
| CR11020A (es) | 2009-10-06 |
| MX2009009699A (es) | 2009-09-24 |
| CL2008000784A1 (es) | 2008-05-30 |
| KR20100015376A (ko) | 2010-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099639A (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil sustituido]-5-fenilimidazolona como inhibidores de ?-secretasa | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| AR065276A1 (es) | Herbicidas de n-oxidos de piridina sustituidos | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| CO6321166A2 (es) | Compuestos de pirrol | |
| AR116978A1 (es) | Fungicidas de tolilo sustituido | |
| AR066459A1 (es) | Derivados de oxadiazol como moduladores de gamma-secretasa. composiciones farmaceuticas | |
| ES2855732T3 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP | |
| PH12013501658A1 (en) | Bridged piperidine derivatives | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR066881A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
| CO6180449A2 (es) | Quinazolinonas y naftiridinonas que incluyen un grupo n-(bifenil-4-ilmetil-n-(piperidin-4-il)acetamida sustituida, utiles para el tratamiento de aterosclerosis | |
| AR110443A1 (es) | Inhibidores de histona metiltransferasas | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| CO6251201A2 (es) | Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| CR10034A (es) | Derivados de oxadiazol | |
| AR087148A1 (es) | Imidazopiridazinas | |
| CO6190554A2 (es) | Compuestos de 4-hidroxi-2-oxo-2, 3-dihidro-1, 3-benzotiazol-7il para la modulacion de la actividad del adrenoreceptor beta2 | |
| AR041440A1 (es) | Lactamicos y sus usos | |
| BR112014007898A2 (pt) | derivados de etinila como moduladores alostéricos de mglur5 | |
| AR077819A1 (es) | Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip) | |
| AR084606A1 (es) | Derivados de biaril-amida | |
| PE20090295A1 (es) | Derivados de espirociclopropilpiperidina |